The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Subscribe To Our Newsletter & Stay Updated
